Key Points
- Insider sale: Director Mark Sawicki sold 1,341 shares on March 23 at an average price of $8.18 for about $10,969, reducing his stake by 1.29% to 102,356 shares (valued at ~$837,272), according to an SEC filing.
- Mixed quarterly results and analyst view: CryoPort reported EPS of ($0.21) versus ($0.19) expected (a miss) but beat revenue estimates with $45.45M, and analysts have a consensus rating of Moderate Buy with a $12.94 average price target.
- Market snapshot: CYRX opened at $8.41 (up ~3.2%), market cap ~$419.3M, P/E 6.37, 50- and 200-day moving averages of $8.90 and $9.32, 12‑month range $4.63–$11.45, and institutional investors own about 92.9% of the stock.
CryoPort, Inc. (NASDAQ:CYRX - Get Free Report) insider Mark Sawicki sold 1,341 shares of the business's stock in a transaction dated Monday, March 23rd. The stock was sold at an average price of $8.18, for a total value of $10,969.38. Following the transaction, the insider directly owned 102,356 shares of the company's stock, valued at $837,272.08. This represents a 1.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
CryoPort Stock Up 3.2%
CYRX opened at $8.41 on Thursday. The firm has a market capitalization of $419.32 million, a P/E ratio of 6.37 and a beta of 1.69. The stock's 50 day moving average price is $8.90 and its two-hundred day moving average price is $9.32. CryoPort, Inc. has a 12-month low of $4.63 and a 12-month high of $11.45.
CryoPort (NASDAQ:CYRX - Get Free Report) last issued its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.21) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by ($0.02). CryoPort had a negative return on equity of 8.22% and a net margin of 42.35%.The business had revenue of $45.45 million for the quarter, compared to analyst estimates of $42.92 million. As a group, analysts anticipate that CryoPort, Inc. will post -0.99 earnings per share for the current year.
Wall Street Analysts Forecast Growth
A number of analysts have weighed in on the stock. Wall Street Zen downgraded shares of CryoPort from a "hold" rating to a "sell" rating in a report on Saturday, March 7th. Needham & Company LLC upped their price objective on shares of CryoPort from $12.00 to $13.00 and gave the company a "buy" rating in a research report on Wednesday, March 4th. Finally, Weiss Ratings reissued a "sell (d+)" rating on shares of CryoPort in a research report on Monday, December 29th. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $12.94.
Get Our Latest Research Report on CryoPort
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Basepoint Wealth LLC acquired a new stake in CryoPort during the fourth quarter valued at approximately $34,000. Tower Research Capital LLC TRC raised its holdings in shares of CryoPort by 300.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company's stock worth $44,000 after buying an additional 4,375 shares in the last quarter. Whittier Trust Co. of Nevada Inc. bought a new position in shares of CryoPort during the 3rd quarter worth approximately $53,000. ProShare Advisors LLC bought a new position in shares of CryoPort during the 2nd quarter worth approximately $75,000. Finally, AlphaQuest LLC acquired a new stake in CryoPort in the 3rd quarter valued at $79,000. Institutional investors own 92.90% of the company's stock.
About CryoPort
(
Get Free Report)
CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.
CryoPort's product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
